Business
ALNOV: Revenue up, DHSC dispute resolved, and cost savings position Novacyt for future growth
ALNOV: Revenue up, DHSC dispute resolved, and cost savings position Novacyt for future growth
About this update from Novacyt Sas
Revenue grew to £10.3m in H1 2024, driven by reproductive health and NIPT, while resolving the DHSC dispute led to exceptional costs and a strong cash position of £32.9m. Integration of Yourgene Health and cost-saving measures support future growth. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.